In brief: Acrux, Proteome Systems, Panbio, Virax
Tuesday, 31 January, 2006
Ross Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.
Dobinson is a founder and former CEO of Acrux and has an 8 per cent interest in the company's shares. Ken Windle, an Acrux director since 2001, has been appointed non-executive deputy chairman.
Following a letter of intent announced at BIO 2005, Proteome Systems (ASX:PXL) has signed a formal agreement with the Bill Gates-funded Foundation for Innovative New Diagnostics (FIND) to develop Proteome's tuberculosis biomarkers for incorporation into a point-of-care test. The agreement details development milestones and financial and non-financial commitments.
Panbio (ASX:PBO) has appointed Peter Burrows as CFO and company secretary permanently. He was originally appointed on an interim basis on August 27.
Virax Holdings (ASX:VHL) has raised a further $600,000 under its rights issue, bringing the total raised to $3.7 million out of $3.8 million. The issue will close on February 15.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
